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Abstract
Background: Vitamin D deficiency is highly prevalent across the globe. Existing studies
suggest that a low vitamin D level is associated with more than 130 outcomes. Exploring
the causal role of vitamin D in health outcomes could support or question vitamin D sup-
plementation.
Methods: We carried out a systematic literature review of previous Mendelian-
randomization studies on vitamin D. We then implemented a Mendelian Randomization–
Phenome Wide Association Study (MR-PheWAS) analysis on data from 339 256
individuals of White British origin from UK Biobank. We first ran a PheWAS analysis to
test the associations between a 25(OH)D polygenic risk score and 920 disease outcomes,
and then nine phenotypes (i.e. systolic blood pressure, diastolic blood pressure, risk of
hypertension, T2D, ischaemic heart disease, body mass index, depression, non-vertebral
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fracture and all-cause mortality) that met the pre-defined inclusion criteria for further
analysis were examined by multiple MR analytical approaches to explore causality.
Results: The PheWAS analysis did not identify any health outcome associated with the
25(OH)D polygenic risk score. Although a selection of nine outcomes were reported in
previous Mendelian-randomization studies or umbrella reviews to be associated with vi-
tamin D, our MR analysis, with substantial study power (>80% power to detect an associ-
ation with an odds ratio >1.2 for per standard deviation increase of log-transformed
25[OH]D), was unable to support an interpretation of causal association.
Conclusions: We investigated the putative causal effects of vitamin D on multiple health
outcomes in a White population. We did not support a causal effect on any of the disease
outcomes tested. However, we cannot exclude small causal effects or effects on out-
comes that we did not have enough power to explore due to the small number of cases.
Key words: 25(OH)D, vitamin D, PheWAS, Mendelian randomization
Introduction
Vitamin D status is an important public-health issue due to
the high prevalence of vitamin D insufficiency and defi-
ciency worldwide.1 Furthermore, it has been reported to be
associated with many non-skeletal outcomes (e.g. cardio-
vascular disease, cognitive impairment and cancer).2 In our
recent umbrella review of meta-analyses of randomized
clinical trials (RCTs) and of observational studies, we have
found that serum 25-hydroxyvitamin D (25(OH)D) or sup-
plemental vitamin D has been linked to more than 130
unique health outcomes.3 However, the majority of the
studies yielded conflicting results and no association was
convincing.3
With large cohorts linked to electronic medical records
(EMRs), the Phenome Wide Association Study (PheWAS)
design has been proposed as a high-throughput approach
to comprehensively evaluate associations between genetic
variants and a wide range of phenotypes (usually generated
by EMR). The PheWAS method has been proven to be use-
ful in the replication of hundreds of known genotype–phe-
notype associations as well the identification of new
associations.4 Since phenotypes defined by EMRs are
largely correlated, Bonferroni correction for a conventional
PheWAS using general linear models is over-conservative.
Thus, a novel Bayesian analysis framework, termed
TreeWAS, has been developed.5 TreeWAS is shown to in-
crease statistical power by up to 20% and can detect new
hits missed by a conventional PheWAS.5
In traditional epidemiological analysis, a causal effect
of 25(OH)D on disease outcomes cannot be unambigu-
ously demonstrated due to the known limitations of obser-
vational research including unmeasured confounding
factors and reverse causality. By using single-nucleotide
polymorphisms (SNPs) associated with 25(OH)D in an in-
strumental variable (IV) analysis, also known as
Mendelian-randomization (MR) analysis, we can largely
overcome these limitations.
In the current study, we first conducted a systematic lit-
erature review of previous MR studies on 25(OH)D. Then,
we analysed 339 256 individuals from the UK Biobank
study by implementing a conventional PheWAS and the
Bayesian TreeWAS for a large number of health outcomes
Key Messages
• Observational studies have identified associations between vitamin D levels and hundreds of disease outcomes.
However, evidence of causality for most of these associations is either lacking or not confirmed by randomized clini-
cal trials or Mendelian-randomization studies.
• With the Mendelian Randomization–Phenome Wide Association Study design, we explored the causal relationships
between vitamin D level and 920 outcomes in the UK Biobank cohort. None of these outcomes was causally associ-
ated with vitamin D at a moderate or higher effect size.
• Small causal effects that we did not have enough power to explore in the present study could be studied in the future
with larger sample sizes to achieve sufficient statistical power.
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based on linked EMRs. Finally, for a selection of outcomes
based on the results from PheWAS/TreeWAS, power and
evidence from previous studies, we performed further MR
analysis.
Methods
Systematic literature review for MR studies on
25(OH)D
The main steps of the study are presented in Figure 1. First,
we carried out a systematic literature review of all pub-
lished MR studies exploring the causal effect of 25(OH)D
levels on any outcome. The Medline and Embase databases
were searched for up to 1 May 2019. For details on the
search strategy and search algorithm, please see
Supplementary Table 1, available as Supplementary data
at IJE online. Any review articles, non-English articles or
conference abstracts were excluded. Studies on the impact
of other markers/exposures on 25(OH)D levels were also
excluded. References from the included studies were
checked to identify any additional relevant studies. The lit-
erature search and review process were done in parallel by
two authors (X.M. and Y.H.). Data extraction was done
by X.M. and then confirmed by Y.H.
Study population
UK Biobank is a very large population-based prospective
study established to allow detailed investigations of genetic
and non-genetic determinants of the diseases in middle- and
old-aged adults.6 More than 500 000 individuals were
recruited between 2006 and 2010, all of whom gave written
consent and underwent baseline measurements, including
questionnaires, interview, anthropometric and clinical meas-
urements. Participants donated blood samples for genotyping
and biomarker analysis. In addition, UK Biobank participants
were linked to their EMR data, including hospital inpatient,
cancer-registry and death-registry data.
In this study, we used the UK Biobank genetic data of
488 378 participants. Genetic quality control was done
centrally by UK Biobank.7 A total of 339 256 unrelated
White British individuals were included in our final analy-
sis (Supplementary Methods, available as Supplementary
data at IJE online).
Creation of weighted 
genetic score for Vitamin D 
 PheWAS 
TreeWAS 
Systematic literature 
review of MR studies 
on Vitamin D  
Evaluation for phenotypes: 
phenotypes that meet 
criteria 1 and 2 go to 
subsequent analysis. 
Criterion 1: Enough power in 
MR analysis. 
Criterion 2: 1) or 2) or 3) 
1) Statistically significant in 
PheWAS or TreeWAS 
2) Statistically significant or 
conflicting evidence from 
previous MR studies. 
3) Classified as probable or 
suggestive by our previous 
umbrella review of vitamin D.3
Merge EMR data with 
self-reported data 
MR analyses: 
Two-stage MR, 
IVW MR, 
Egger’s MR 
Figure 1. Study flowchart.
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Statistical analysis
We implemented all statistical analyses using R 3.3.2. We
used the R package developed by Carroll et al. for the
PheWAS analysis.8 We used the R package developed by
Cortes et al. for the TreeWAS analysis.5
Creation of 25(OH)D genetic-risk score
We created a genetic-risk score for 25(OH)D. In the selection
of variants, we used the results from the largest genome-wide
association study (GWAS) on 25(OH)D in a White popula-
tion with a total of 79 336 individuals of European ancestry
(the SUNLIGHT GWAS).9 The SUNLIGHT GWAS identi-
fied six independent loci associated with serum 25(OH)D
concentration that explained 2.84% of the trait variance:
rs3755967 (GC), rs12785878 (NADSYN1/DHCR7),
rs10741657 (CYP2R1), rs17216707 (CYP24A1),
rs10745742 (AMDHD1) and rs8018720 (SEC23A). We cre-
ated a genetic score by adding the number of effect alleles car-
ried in each of the six SNPs and weighted based on their
effect estimates from the SUNLIGHT GWAS.
PheWAS/TreeWAS analysis
The association between the genetic-risk score and common
confounders was first tested. In the PheWAS analysis, we
only included disease groups with more than 200 cases, as
suggested by a simulation of power estimates for PheWAS
analysis.10 We then applied logistic-regression adjusting for
gender, age, body mass index (BMI), the UK Biobank assess-
ment centre attended, east and north co-ordinates of home
address, and the first five ancestral principal components. A
total of 920 disease phenotypes were tested and a P-value of
<5.44 10–5 was regarded as statistically significant based
on Bonferroni correction (0.05/920¼5.44 10–5).
We also applied the TreeWAS Bayesian analysis. The
case–control status of participants was defined by their
ICD10 codes (from hospital episode, cancer-registry and
death-registry data). Due to the complexity of converting
ICD9 codes into ICD10 codes, records of ICD9 were dis-
carded. The same weighted genetic-risk score was
employed to test the association between the score and all
ICD10 codes presented in UK Biobank data. In our
TreeWAS analysis, nodes with posterior probability (PP) of
a non-zero effect >0.75 were considered as significant.5
MR analysis
For those phenotypes for which there was enough statistical
power for a MR study (>80%) and (i) were statistically sig-
nificant in the aforementioned PheWAS/TreeWAS analysis or
(ii) were classified as probable or suggestive in our previous
umbrella review3 or (iii) were found to be statistically signifi-
cant or with conflicting evidence in previous MR studies,
we implemented MR analysis to further control for bias and
assess the causality of the observed associations. To increase
the statistical power, we used UK Biobank self-reported medi-
cal conditions to include cases that were not captured by
EMR data. With power calculation, we estimated that we
had 80% power to detect a causal odds ratio (OR) of 1.2 for
outcomes with more than 9977 cases assuming that the ge-
netic instrument explains 2.84% of the variance of 25(OH)D
levels and that the case:control ratio was 1:5 or larger at
alpha¼ 0.05 level.11 For these outcomes, we then ran MR
analyses using multiple methods: (i) two-stage MR, (ii) inverse
variance weighted (IVW) MR and (iii) Egger’s regression MR
(Supplementary Methods, available as Supplementary data at
IJE online). In addition, we constructed the identical genetic-
risk score in 2821 control individuals of the Study of
Colorectal Cancer in Scotland (SOCCS) (see Supplementary
Methods, available as Supplementary data at IJE online, for a
description of the SOCCS study) to estimate the variance of
25(OH)D levels explained by this score and the corresponding
F-statistics, given that we did not have individual 25(OH)D-
level data from the UK Biobank.
Results
Systematic literature review of 25(OH)D MR
studies
After applying our inclusion and exclusion criteria, 63 MR
studies were included in our systematic literature review
(Supplementary Figure 1, available as Supplementary data at
IJE online). The causal effect of vitamin D has been exam-
ined across a range of disease outcomes and a causal role of
vitamin D is not supported for the majority of them. Disease
outcomes that were ever reported to be causally associated
with vitamin D levels include type 2 diabetes (T2D), total adi-
ponectin, diastolic blood pressure (DBP), risk of hyperten-
sion, multiple sclerosis, Alzheimer’s disease, all-cause
mortality, cancer mortality, mortality excluding cancer and
cardiovascular events, ovarian cancer, HDL-cholesterol, tri-
glycerides, high-density lipoprotein, delirium and cognitive
functions. However, for some of these outcomes, the evidence
across different MR studies is not consistent. Detailed results
of the systematic review of previous MR studies are present
in Supplementary Methods, available as Supplementary data
at IJE online, and Supplementary Table 2, available as
Supplementary data at IJE online.
Descriptive analysis of the included UK Biobank
participants
We included 339 256 British White unrelated individuals
from the UK Biobank cohort, 53.68% of whom
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were female. All six SNPs satisfied the Hardy-Weinberg
equilibrium test (Table 1 and Supplementary Table 3,
available as Supplementary data at IJE online). The associ-
ation between the score of six SNPs and common con-
founding factors is presented in Table 2. Except for the UK
Biobank assessment centre (P¼ 1.30 10–17), all other
confounding factors were not associated with the score.
We then tested the associations between the SNPs and the
geographic regions (England and Wales vs Scotland) and
found that two SNPs (rs12785878 and rs10745742) were
unevenly distributed across the UK. Since we have adjusted
for the assessment centre and latitude as covariates, we did
not expect the association between score and assessment
centre to bias our results.
PheWAS and TreeWAS
In the conventional PheWAS, we tested associations be-
tween the score and 920 outcomes (>200 cases). No asso-
ciations survived the Bonferroni multiple-testing
correction. There were only two phenotypes with a P-value
<0.001 that were reported as suggestive associations, in-
cluding delirium (517 cases, P¼ 1.83 10–4) and ne-
phrotic syndrome (374 cases, P¼ 9.75 10–4) (Figure 2
and Supplementary Table 4, available as Supplementary
data at IJE online). The P-value for the association be-
tween the score and vitamin D deficiency was 0.00116
(291 cases), which was the third smallest P-value among
all tested associations. We additionally performed a sensi-
tivity analysis without adjustment for BMI (Supplementary
Table 5, available as Supplementary data at IJE online)
and the results showed no difference in the significance of
PheWAS associations when compared to that with adjust-
ment for BMI (Supplementary Table 4, available as
Supplementary data at IJE online).
In the TreeWAS, the largest PP for all tested phenotypes
was 0.26, which was for the calculus of the ureter (ICD10
code, N20.1). Since a PP >0.75 was needed to take find-
ings from the TreeWAS forward, there were no putative
associations found from the TreeWAS analysis.
MR analysis
Based on our eligibility criteria, the following outcomes
were selected to be further examined using MR: systolic
blood pressure (SBP), DBP, risk of hypertension, risk of
T2D, risk of ischaemic heart disease (IHD), BMI, risk of
depression, risk of non-vertebral fracture and all-cause
mortality. Incorporating self-reported data increased the
numbers of cases for some of the outcomes (Table 3). We
first applied linear regression between the genetic-risk
score and measured plasma 25(OH)D levels in the controls
from the SOCCS study (N¼ 2821). The R2 value was
1.61% and the F-statistic was 45.96, indicating that the ge-
netic-risk score is a strong IV for our MR analysis.12 We
then applied the second stage of the MR analysis and we
did not observe any causal effects for all the tested out-
comes. Results from the three different MR methods were
consistent (Table 4). Additionally, for the MR Egger’s re-
gression, the P-value of the intercept term for all outcomes
was >0.05, indicating no evidence of unbalanced pleiot-
ropy (Supplementary Table 6, available as Supplementary
data at IJE online) among the variants we used.
Table 1. Demographic characteristics of the UK Biobank par-
ticipants and genotype counts of the six SNPs included in the
genetic-risk score
Variable Value
Demographic characteristics (n ¼ 339 256)
Female 182 110 (53.68%)
Age 56.89 (7.99) years
BMI 27.40 (4.76) kg/m2
Genotype counts
rs3755967 polymorphism (n¼338 753)
CC 169 710 (50.10%)
CT 140 206 (41.39%)
TT 28 837 (8.51%)
Hardy-Weinberg test P-value 0.52
rs10741657 polymorphism (n ¼ 339 256)
AA 55 617 (16.39%)
AG 163 064 (48.07%)
GG 120 575 (35.54%)
Hardy-Weinberg test P-value 0.83
rs12785878 polymorphism (n ¼ 339 256)
TT 211 627 (62.38%)
TG 112 585 (33.19%)
GG 15 044 (4.43%)
Hardy-Weinberg test P-value 0.35
rs10745742 polymorphism (n ¼ 336 987)
TT 47 797 (14.18%)
TC 158 392 (47.00%)
CC 130 798 (38.82%)
Hardy-Weinberg test P-value 0.29
rs8018720 polymorphism (n ¼ 339 256)
GG 10 666 (3.14%)
GC 98 435 (29.02%)
CC 230 155 (67.84%)
Hardy-Weinberg test P-value 0.80
rs17216707 polymorphism (n ¼ 324 016)
TT 216 735 (66.89%)
TC 96 403 (29.75%)
CC 10 878 (3.36%)
Hardy-Weinberg test P-value 0.78
Continuous variables are presented as mean (standard deviation), whereas
categorical variables are presents as N (%).
BMI, body mass index.
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Discussion
Main findings
In order to investigate the safety and rationale of
population-wide measurements to raise vitamin D levels
(such as fortification of staple food with vitamin D), we
conducted a high-throughput PheWAS/TreeWAS study on
more than 920 outcomes in a UK Biobank sample of
339 256 British White individuals, followed by MR analy-
ses for selected outcomes. The large sample size ensured
the study was well powered to detect moderate to large
causal effects (OR >1.2) for outcomes with more than
9997 cases.
The PheWAS/TreeWAS analysis used a weighted ge-
netic score of six SNPs as a proxy of the genetically deter-
mined 25(OH)D level and examined its association across
Table 2. Association of the instrumental variable (weighted genetic-risk score) with potential confounding factors
Continuous Categorical
Confounding factors Beta (SE) P-value F-value P-value
Age 0.156 (0.202) 0.441
BMI 0.224 (0.121) 0.063
Time spend outdoors in summer –0.077 (0.091) 0.394
Time spend outdoors in winter 0.083 (0.119) 0.485
Sex 0.455 0.500
Assessment centre 6.164 1.3010–17a
Average household income before tax 1.213 0.296
Qualification 0.490 0.843
Alcohol intake frequency 1.419 0.203
Univariate linear regression was conducted for continuous confounding factors and analysis of variance was conducted for categorical factors.
aP<0.05.
Figure 2. Manhattan plot for results of PheWAS analysis. Phenotypes aggregated on International Classification of Disease codes were plotted with
the –log10 P-value of each association. The first line indicates a Bonferroni-corrected P-level of 5.44 10–5 and the second line indicates a P-level of
0.001. No phenotype survived Bonferroni correction. There were only two phenotypes with a P-value <0.001, which were delirium (P¼ 1.83 10–4)
and nephrotic syndrome (P¼ 9.7510–4).
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a wide range of disease outcomes. In this initial scan, we
did not observe any significant associations with adjust-
ment for a number of covariates. Additionally, given that
there is much debate in the literature suggesting not to ad-
just for heritable covariates in genome-wide association
studies,13 we performed a sensitivity analysis without BMI
as a covariate. There were some differences in the actual ef-
fect sizes, but the direction and statistical significance of
the PheWAS associations were consistent between the two
models.
We then integrated EMR data with self-reported medi-
cal conditions for the final MR analysis and explored the
causal effect of vitamin D on SBP, DBP, risk of hyperten-
sion, T2D, IHD, BMI, risk of depression, non-vertebral
fracture and all-cause mortality. This merged dataset in-
creased the number of cases and re-assigned spurious con-
trols, thus increasing the study power. For outcomes tested
in MR, we had statistical power of nearly 100% for detect-
ing a true effect of or larger than 1.2, except for all-cause
mortality (85% power). The estimated causal-effect sizes
for all outcomes were close to null with narrow confidence
intervals, which suggested that there is no moderate to
large causal effect of 25(OH)D on the nine tested
outcomes.
Among these nine outcomes, associations between vita-
min D and blood pressure, hypertension, T2D, IHD and
BMI were suggestive from previous observational studies
and RCTs.3 Conflicting evidence exists for blood pressure
and T2D from previous MR studies.14–18 Previous MR
studies for IHD and BMI did not support causal associa-
tions.19–22 Although associations between vitamin D and
the risk of depression and non-vertebral fracture were sug-
gestive from observational studies and RCTs, our MR
analysis found no evidence of causality for their
associations. These finding are further supported by the re-
cently published MR studies,23,24 in which the effects of vi-
tamin D on major depression (59 851 cases)23 and fracture
(185 057 cases)24 are investigated, respectively, but none
of them supports any causality. In agreement with MR
findings, a recent systematic literature review and
meta-analysis investigating the effect of calcium, vitamin D
or a combination of calcium and vitamin D supplements
on the incidence of fractures (33 RCTs included, involving
51 145 participants) did not find any association between
vitamin D or calcium plus vitamin D supplements and the
incidence of non-vertebral fractures.25 There was no evi-
dence on the association between vitamin D and all-cause
mortality from previous observational studies and RCTs,
although a previous MR study reported a significant effect
[10 349 deaths, 95 766 total participants, OR¼ 1.30, 95%
confidence interval (CI): 1.05 to 1.61].26 This study
employed four SNPs in two loci (DHCR7 and CYP2R1) as
their IV, which explained only 1.0% of the variance for the
25(OH)D level. However, in our study with 85% power
for detecting an effect of 1.2 and with a comparable case
size (N¼ 9830 deaths), we did not observe a causal effect
(OR¼ 1.030, 95% CI: 0.869 to 1.222, P¼0.671). The as-
sociation between vitamin D and all-cause mortality needs
to be studied by a larger MR or meta-analysis of MR
studies.
Strengths and limitations
Our study has several strengths. This is the first study to in-
vestigate the causal effect of vitamin D in a large sample of
339 256 individuals across the whole spectrum of disease
outcomes. Taking advantage of the PheWAS design, we
tested the association between the 25(OH)D genetic-risk
Table 3. Number of cases in Mendelian-randomization analysis
Outcomes N totala N, EMRb N, SRc N, bothd
SBPe 319 778 NA NA NA
DBPe 319 779 NA NA NA
hypertension 106 405 16 905 (15.9%) 42 317 (39.8%) 47 183 (44.3%)
T2D 15 958 13 692 (85.8%) 671 (4.2%) 1595 (10.0%)
IHD 28 337 13 062 (46.1%) 2556 (9.0%) 12 719 (44.9%)
BMIe 338 172 NA NA NA
Depression 23 294 5382 (23.1%) 13 628 (58.5%) 4284 (18.4%)
Non-vertebral fracture 23 603 15 811 (67.0%) 6382 (27.0%) 1410 (6.0%)
All-cause mortality 9830 9830 (100%) NA NA
EMR, electronic medical records; SR, self-reported medical conditions; SBP, systolic blood pressure; DBP, diastolic blood pressure; T2D, type 2 diabetes; IHD,
ischaemic heart disease; BMI, body mass index.
aTotal number of cases.
bNumber of cases captured by EMR data only.
cNumber of cases captured by SR data only.
dNumber of cases captured by both EMR and SR.
eContinuous variable, data come from baseline anthropometric measurement data.
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score and a wide spectrum of phenotypes. Then, we ap-
plied multiple MR methods, including two-stage MR, IVW
MR and Egger’s MR, to explore the causal effect and test
the robustness of our findings across multiple methods.
The study also has some limitations. In our analysis, we
only included White individuals residing at a high latitude,
which may hinder the generalizability of our findings to other
populations. The weights we employed in the score creation
were from a meta-analysis of GWAS,9 which covered individ-
uals residing in multiple countries. Therefore, the distribution
of vitamin D levels in the UK population may be different
from that in the wider White population and thus the
actual coefficients for variants might also differ. Another
implication of the high latitude is that, in the UK Biobank
population, an overall low 25(OH)D level (independent of
genetic variation but due to a lack of adequate sunlight expo-
sure) may increase the risk of vitamin D-related disease.
Therefore, small changes in 25(OH)D levels due to genetic
variation may not affect the disease risks further.
Furthermore, the variance of 25(OH)D explained by the six
SNPs was 2.84% from the SUNLIGHT GWAS and 1.61%
from the SOCCS controls. Although the F-statistics indicates
Table 4.Mendelian-randomization causal-effect estimates for nine selected outcomes
Method beta se P-value OR 95% CI N total/N cases Power
Systolic blood pressure 319 778 NA
Two-stage MR –0.669 0.449 0.137 NA NA
IVW MR –0.648 0.451 0.210 NA NA
Egger’s regression –0.180 1.086 0.876 NA NA
Diastolic blood pressure 319 779 NA
Two-stage MR –0.121 0.251 0.629 NA NA
IVW MR –0.117 0.251 0.661 NA NA
Egger’s regression 0.491 0.530 0.407 NA NA
Hypertension 339 256/106 405 1.00/0.99
Two-stage MR –0.056 0.059 0.343 0.976 0.928–1.026
IVW MR –0.063 0.060 0.340 0.973 0.911–1.040
Egger’s regression 0.084 0.175 0.657 1.037 0.841–1.278
Type 2 Diabetes 339 256/15 958 0.97/0.51
Two-stage MR –0.060 0.126 0.632 0.974 0.876–1.083
IVW MR –0.067 0.126 0.617 0.971 0.845–1.117
Egger’s regression 0.242 0.244 0.377 1.110 0.829–1.485
Ischaemic heart disease 339 256/28 337 1.00/0.74
Two-stage MR 0.049 0.096 0.611 1.021 0.942–1.107
IVW MR 0.047 0.096 0.647 1.020 0.917–1.135
Egger’s regression 0.109 0.219 0.645 1.048 0.807–1.360
Body mass index 338 172 NA
Two-stage MR 0.128 0.120 0.288 NA NA
IVW MR 0.130 0.121 0.329 NA NA
Egger’s regression –0.099 0.213 0.665 NA NA
Depression 339 256/23 294 0.99/0.66
Two-stage MR –0.216 0.102 0.034 0.911 0.837–0.993
IVW MR –0.212 0.102 0.093 0.913 0.816–1.022
Egger’s regression –0.311 0.180 0.158 0.875 0.706–1.084
Non-vertebral fracture 339 256/23 603 1.00/0.66
Two-stage MR –0.068 0.101 0.497 0.971 0.892–1.057
IVW MR –0.074 0.101 0.495 0.969 0.867–1.083
Egger’s regression –0.092 0.265 0.747 0.961 0.700–1.320
All-cause mortality 339 256/9830 0.85/0.35
Two-stage MR 0.073 0.154 0.634 1.032 0.907–1.175
IVW MR 0.069 0.154 0.671 1.030 0.869–1.222
Egger’s regression 0.192 0.272 0.520 1.086 0.785–1.503
MR effect estimates were done with three different MR methods. OR was calculated as exponential of beta SD [the standard deviation (SD) of the log-trans-
formed 25(OH)D level in an independent British population, SOCCS, which was 0.430], whose unit was per SD increase in log-transformed 25(OH)D levels. The
upper/lower 95% CI was calculated similarly; with the same unit as the OR. Power was calculated assuming a R2 value of 0.0284, OR of 1.2/1.1 and significance
level at 0.05.
MR, Mendelian randomization; IVW, inverse variance weighted; OR, odds ratio.
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a robust instrument, the variance explained is low.
Moreover, considering participants in the UK Biobank are
not representative of the UK population and there is evidence
of a ‘healthy volunteer’ selection bias,27 it is possible that the
healthy volunteer selection bias observed may contribute to
the null findings in this study.
Furthermore, the relationship between the 25(OH)D
level and the risk of diseases may be nonlinear. As shown
by previous studies, vitamin D supplementation only
shows treatment effects among individuals with baseline
25(OH)D levels of no more than 30 nmol/L. When all par-
ticipants were analysed irrespective of their baseline
25(OH)D levels, there was no treatment effect.28,29 Thus,
the effect of 25(OH)D on health outcomes may differ by
baseline serum 25(OH)D level. Considering the potential
divergent 25(OH)D levels of the UK population, it is possi-
ble that we missed the true association between 25(OH)D
levels and diseases among individuals of certain 25(OH)D
levels.
Although we incorporated EMR data and self-reported
medical conditions in our definition of phenotypes, problems
with reporting bias could have occurred in outcome defini-
tion. Incorporation of more data, including general-practice
data, outpatient data, prescription data and even imaging
data, would help improve the validity of case definition in
PheWAS studies. We set the minimum case number per phe-
notype based on a simulation analysis of PheWAS power esti-
mates.10 We therefore restricted the PheWAS analysis to
outcomes with >200 cases. From PheWAS analysis, we
noted that the association between the genetic score of the
25(OH)D levels and vitamin D deficiency was not significant.
This is probably due to the limited statistical power. In partic-
ular, only 291 cases with vitamin D deficiency were identified
in this cohort of 339 256 individuals, which is much fewer
than would be expected if 25(OH)D levels were systemati-
cally tested. Additionally, for the MR analyses, we explored
only nine outcomes with more than 80% power. There were
some outcomes that had been shown to be associated with vi-
tamin D in previous MR studies, including total
adiponectin,30 multiple sclerosis,31 Alzheimer’s disease,32
cancer mortality,26 mortality excluding cancer and cardiovas-
cular events,26 ovarian cancer,33 HDL-cholesterol,16
triglycerides16 and cognitive functions,34 but, due to limited
statistical power or data availability, we did not include them
in our final MR analysis.
Conclusion
Our study suggested that there was no evidence of a large
to moderate (OR>1.2) causal effect of vitamin D on a
number of health outcomes, particularly for SBP, DBP, the
risk of hypertension, T2D, IHD, BMI, depression, non-
vertebral fracture and all-cause mortality. Further, larger
studies, probably involving the joint analysis of data from
several large biobanks, may be needed to investigate
smaller causal effects that nevertheless could be important
for public health due to the high prevalence of low vitamin
D levels in many populations.
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